Appendix 2 from Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Open Access
- 31 March 2023
- other
- Published by American Association for Cancer Research (AACR)